Sarcoma & GIST
Feature
Can an app guide cancer treatment decisions during the pandemic?
Conference Coverage
Three years of imatinib may halve death rate in GIST
Receiving imatinib for 3 years rather than 1 year improved overall survival by 50% and recurrence-free survival by 30%.
Feature
‘A good and peaceful death’: Cancer hospice during the pandemic
Conference Coverage
Germline testing in advanced cancer can lead to targeted treatment
In a study of nearly 12,000 cancer patients, 7%-9% of patients had targetable germline alterations.
News
Oncologists’ income and satisfaction are up
News from the FDA/CDC
FDA approves pomalidomide for Kaposi sarcoma
Conference Coverage
Video coaching may relieve anxiety and distress for long-distance cancer caregivers
Conference Coverage
ASCO goes ahead online, as conference center is used as hospital
From the Journals
Excess cancer deaths predicted as care is disrupted by COVID-19
Feature
ASCO panel outlines cancer care challenges during COVID-19 pandemic
Feature
Will coronavirus restrictions lead to more advanced cancers?